medigraphic.com
ISSN 2007-6800 (Print)

2012, Number 1

<< Back Next >>

Rev Mex Traspl 2012; 1 (1)

Long-term experience of the kidney transplantation program of the Regional Hospital of Veracruz, Mexico

Hernández-Jiménez JD, Hernández-Navarrete LS, Rodríguez-Fernández A, Jiménez-López LA, Varela-Pérez V, Irigoyen-Castillo A, Ávila-Pardo SF, Martínez-Mier G

Language: Spanish
References: 15
Page: 15-21
PDF size: 125.28 Kb.


ABSTRACT

Introduction: Kidney transplant is the best therapy for most of the patients with end-stage chronic kidney failure. In the Regional Hospital of High Specialty of Veracruz, the Organ Procurement Committee began on August 1st of 2005 and the Kidney Transplantation Program on September 21 of 2006. Objective: To describe the experience of the Kidney Transplantation Program of our hospital, emphasizing in the patient/graft survival rate. Material and methods: Retrospective study of kidney transplants performed in our hospital from September 21 of 2006 to the present. Sociodemographic variables, transplant-related variables, serologic status of citomegalovirus, complications, induction, initial and actual immunosuppression were registered. We evaluated acute rejection, kidney function, number and type of infections, causes of death and graft lost. Patient survival and graft non-censored survival to the first, third and fifth year after the transplant was calculated with Kaplan-Meier (log-rank). Results: We performed 79 kidney transplants, 35 of living donor and 44 of deceased donor. The global patient survival at 1, 3 and 5 years was 94.9, 93.4 and 82.3% respectively. The global graft survival non-censored at 1, 3 and 5 years was 87.6, 79.7 y 61.5% respectively. The infections were significative in the decreased global survival. Conclusion: It is possible to have a transplantation program predominantly of deceased donor with great results at short and intermediate term, with current immunosuppression therapy, even so we still have to emphasize in the prophylaxis.


REFERENCES

  1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, MaCintosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.

  2. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.

  3. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.

  4. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011 [citado 11-jul-2012]. Disponible en: http://www.srtr.org/annual_reports/2010/.

  5. Collaborative Transplant Study. University of Heidelberg Department of Transplantation Immunology [actualizado 1-May-2012; citado 11 julio de 2012]. Disponible en: http://www.ctstransplant.org/public/graphics/sample.shtml

  6. Noyola-Villalobos HF, Alberu-Gómez J, Gracida C et al. FERT Results (Results of the collaborative retrospective study in renal transplantation in Mexico). Transplantation 2010; 90 (2S): 926.

  7. Marino-Vázquez LA, Sánchez-Ugarte R, Morales-Buenrostro LE. Trasplante renal: primeros mil trasplantes en el Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán en la Ciudad de México. Rev Invest Clin 2011; 63 (Supl 1): 6-13.

  8. Mancilla-Urrea E, Aburto-Morales S, Kasep-Bahena J, Rodríguez-Castellanos F. Programa de trasplante renal en el Instituto Nacional de Cardiología Ignacio Chávez. Rev Invest Clin 2011; 63 (Supl 1): 14-18.

  9. Arellano-Torres EM, Guerrero-González E, Sánchez-Ramírez H et al. Trasplante renal. Experiencia en el Hospital Universitario José E. González, UANL, en Monterrey, México. Rev Invest Clin 2011; 63 (Supl 1): 25-29.

  10. Reyes-Acevedo R, Romo-Franco L, Delgadillo-Castañeda R et al. Programa de trasplante renal del centenario Hospital Miguel Hidalgo en Aguascalientes, México. Rev Invest Clin 2011; 63 (Supl 1): 30-37.

  11. González-Audiffred N, Alfaro-Abúndiz FG, Aranda-Verástegui F et al. Experiencia en trasplante renal, de 1999-2011, en el Hospital Central Dr. Ignacio Morones Prieto de San Luis Potosí. Rev Invest Clin 2011; 63 (Supl 1): 38-43.

  12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.

  13. Martínez-Mier G, Ávila-Pardo SF, Méndez-Lopez MT, Budar-Fernández LF. Long-term results after conversion from calcineurin inhibitors to sirolimus in renal transplant patients. Clin Transplant 2010; 24 (4): 467-73.

  14. Goldfarb-Rumyantzev AS, Hurdle JF, Scandling JD, Baird BC, Cheung AK. The role of pretransplantation renal replacement therapy modality in kidney allograft and recipient survival. Am J Kidney Dis 2005; 46 (3): 537-549.

  15. Caliskan Y, Yazici H, Gorgulu N et al. Effect of pretransplant dialysis modality on kidney transplantation outcome. Perit Dial Int 2009; 29 (Suppl. 2): S117-S122.




2020     |     www.medigraphic.com